financetom
Business
financetom
/
Business
/
Intel Shares Are Climbing Higher Thursday: What's Going On?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Intel Shares Are Climbing Higher Thursday: What's Going On?
Oct 24, 2025 7:52 AM

Intel Corporation ( INTC ) shares are trading higher Friday after the company reported third quarter earnings per share and sales above expectations.

INTC is demonstrating bullish strength. Get the market research here.

What To Know: Intel ( INTC ) reported adjusted earnings of 23 cents per share, topping the consensus estimate of 1 cent. Revenue came in at $13.65 billion, above the expected $13.13 billion.

The Client Computing Group generated $8.5 billion in revenue, up 5% year-over-year, offsetting a 1% decline in Data Center and AI segment sales to $4.1 billion. Total Intel Products revenue rose 3% to $12.7 billion.

Gross margin expanded to 40% on a non-GAAP basis, up 22 percentage points from a year ago, while operating margin improved 29 points to 11.2%.

CEO Lip-Bu Tan said AI is accelerating demand for compute and creating "attractive opportunities across our portfolio." The company also announced $8.9 billion in U.S. government funding and new investments from NVIDIA and SoftBank totaling $7 billion to strengthen its semiconductor operations.

Q4 Outlook: The company sees adjusted earnings per share of 8 cents, versus the consensus estimate of 8 cents. Furthermore, Intel ( INTC ) expects sales between $12.80 billion and $13.80 billion, versus the consensus estimate of $13.37 billion.

Analyst Changes: Following the earnings report, multiple analysts issued price target adjustments.

Mizuho analyst Vijay Rakesh maintained a Neutral rating on Intel ( INTC ) and raised the price target from $39 to $41.

Morgan Stanley analyst Joseph Moore maintained an Equal-Weight rating on Intel ( INTC ) and raised the price target from $36 to $38.

Wedbush analyst Matt Bryson maintained a Neutral rating on Intel ( INTC ) and raised the price target from $20 to $30.

JP Morgan analyst Harlan Sur maintained an Underweight rating on Intel ( INTC ) and raised the price target from $21 to $30.

Rosenblatt analyst Kevin Cassidy maintained a Sell rating on Intel ( INTC ) and raised the price target from $14 to $25.

Related Link: Supermicro Taps New AMD Chips For Its Next-Gen Data Center Push

INTC Price Action: At the time of writing, Intel ( INTC ) shares are trading 1.35% higher at $38.67, according to data from Benzinga Pro.

Image via Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Exclusive-Energy trader Vitol eyes $3 billion sale of US shale producer, sources say
Exclusive-Energy trader Vitol eyes $3 billion sale of US shale producer, sources say
Mar 27, 2025
NEW YORK (Reuters) - Global commodities trader Vitol is exploring a sale of its VTX Energy Partners business, in a deal that could value the U.S. shale oil and gas producer at as much as $3 billion, including debt, people familiar with the matter said. The move aims to capitalize on the fact that the VTX oil and gas business...
Rosenberg Research Sees
Rosenberg Research Sees "Big" Negative Hit to Canada's Economy From Latest U.S. Auto Tariffs
Mar 27, 2025
08:09 AM EDT, 03/27/2025 (MT Newswires) -- United States President Donald Trump finally did it late Wednesday and lowered the boom on the global automotive sector, with the most negative implications for Mexico and Canada -- the only leniency saved for U.S. parts manufacturers who serve the domestic market, said Rosenberg Research. The North American motor vehicle supply chain has...
Wishpond Collaborating With Venops
Wishpond Collaborating With Venops
Mar 27, 2025
08:05 AM EDT, 03/27/2025 (MT Newswires) -- Wishpond Technologies Ltd. ( WPNDF ) , a provider of AI-enabled marketing-focused online business solutions, announced Thursday a collaboration agreement with Venops Inc., a player in healthcare regulatory compliance and consulting services, to market and sell Wishpond's ( WPNDF ) AI-powered SalesCloser platform, white-labeled as 'Provencis', to clients in the medical industry. ...
Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder
Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder
Mar 27, 2025
The U.S. Food and Drug Administration (FDA) on Wednesday approved Soleno Therapeutics, Inc.’s Vykat XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS). Prader-Willi syndrome is a genetic condition characterized by hyperphagia (insatiable hunger) that affects a child’s metabolism, body, and behavior. The company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved